Tissue Sample

PROCEDURE8 trials

Sponsors

Nasser Hanna, M.D., M.D. Anderson Cancer Center, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Manchester University NHS Foundation Trust, Centre Hospitalier Universitaire de Nice

Conditions

Bone CancerBreast CancerEsophageal CancerHereditary CancerNephrotic SyndromeSolid TumorSolid Tumor, AdultSolid Tumor, Unspecified, Adult

Phase 2

Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas

CompletedNCT00319735

Nasser Hanna, M.D.Esophageal Cancer

Start: 2006-04-30End: 2009-01-31Updated: 2016-04-28

Phase 3

3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erithematosus Study Protocol

Active, not recruitingNCT05458622

University Hospital, BrestSystemic Lupus Erythematosus (SLE)

Start: 2022-11-29End: 2026-11-01Target: 25Updated: 2026-06-26

Unknown Phase

Retrospective Study of the Biomechanical Properties of Large Allografts

TerminatedNCT00632294

M.D. Anderson Cancer CenterBone Cancer

Start: 2007-12-31End: 2009-09-30Updated: 2012-08-01

Monitoring Plasma Tumor DNA in Early-Stage Breast Cancer

CompletedNCT02743910

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBreast Cancer

Start: 2016-07-01End: 2026-03-02Updated: 2026-07-09

The Impact of Abdominal Wall Closure Technique on Incidence of Incisional Hernia in Kidney Transplantation

RecruitingNCT03959904

Manchester University NHS Foundation TrustSurgery--Complications

Start: 2020-03-10End: 2026-06-30Target: 50Updated: 2025-05-09

From Immune System Damage to Podocyte Cell Damage: Prospective Database and Biological Collection of Patients (Children and Adults) With MGLS and HSFP

RecruitingNCT04174066

Centre Hospitalier Universitaire de NiceNephrotic Syndrome

Start: 2020-05-20End: 2031-05-20Target: 144Updated: 2026-06-22

3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erythematosus Study Protocol 2

CompletedNCT05747651

University Hospital, BrestSystemic Lupus Erythematosus (SLE)

Start: 2023-03-27End: 2025-10-08Updated: 2026-06-26

UCSF Biobank for Hereditary Cancers and Tumor-Associated Mutations

WithdrawnNCT06895681

University of California, San FranciscoHereditary Cancer, Solid Tumor, Solid Tumor, Adult +2

Start: 2026-08-31End: 2035-12-31Updated: 2026-09-02

Related Papers

Circulating tumor DNA, pathologic response after neoadjuvant therapy, and survival: First results from TBCRC 040 (the PREDICT-DNA trial).

Journal of Clinical Oncology2025-05-287 citations